240 related articles for article (PubMed ID: 31385866)
1. The use of molecular markers for cervical screening of women living with HIV in South Africa.
Kremer WW; van Zummeren M; Breytenbach E; Richter KL; Steenbergen RDM; Meijer CJLM; Dreyer G
AIDS; 2019 Nov; 33(13):2035-2042. PubMed ID: 31385866
[TBL] [Abstract][Full Text] [Related]
2. Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis.
Dick S; Kremer WW; De Strooper LMA; Lissenberg-Witte BI; Steenbergen RDM; Meijer CJLM; Berkhof J; Heideman DAM
Gynecol Oncol; 2019 Aug; 154(2):368-373. PubMed ID: 31182225
[TBL] [Abstract][Full Text] [Related]
3. FAM19A4/miR124-2 methylation analysis as a triage test for HPV-positive women: cross-sectional and longitudinal data from a Dutch screening cohort.
Vink FJ; Lissenberg-Witte BI; Meijer CJLM; Berkhof J; van Kemenade FJ; Siebers AG; Steenbergen RDM; Bleeker MCG; Heideman DAM
Clin Microbiol Infect; 2021 Jan; 27(1):125.e1-125.e6. PubMed ID: 32222459
[TBL] [Abstract][Full Text] [Related]
4. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study.
Bonde J; Floore A; Ejegod D; Vink FJ; Hesselink A; van de Ven PM; Valenčak AO; Pedersen H; Doorn S; Quint WG; Petry KU; Poljak M; Stanczuk G; Cuschieri K; de Sanjosé S; Bleeker M; Berkhof J; Meijer CJLM; Heideman DAM
Int J Cancer; 2021 Jan; 148(2):396-405. PubMed ID: 32997803
[TBL] [Abstract][Full Text] [Related]
5. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).
Luttmer R; De Strooper LM; Berkhof J; Snijders PJ; Dijkstra MG; Uijterwaal MH; Steenbergen RD; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; Van Baal WM; Graziosi PG; Quint WG; Heideman DA; Meijer CJ
Int J Cancer; 2016 Feb; 138(4):992-1002. PubMed ID: 26317579
[TBL] [Abstract][Full Text] [Related]
6. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
7. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
De Strooper LMA; Berkhof J; Steenbergen RDM; Lissenberg-Witte BI; Snijders PJF; Meijer CJLM; Heideman DAM
Int J Cancer; 2018 Sep; 143(6):1541-1548. PubMed ID: 29663363
[TBL] [Abstract][Full Text] [Related]
8. Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping.
Dick S; Vink FJ; Heideman DAM; Lissenberg-Witte BI; Meijer CJLM; Berkhof J
Br J Cancer; 2022 Feb; 126(2):259-264. PubMed ID: 34743198
[TBL] [Abstract][Full Text] [Related]
9. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.
De Strooper LMA; Verhoef VMJ; Berkhof J; Hesselink AT; de Bruin HME; van Kemenade FJ; Bosgraaf RP; Bekkers RLM; Massuger LFAG; Melchers WJG; Steenbergen RDM; Snijders PJF; Meijer CJLM; Heideman DAM
Gynecol Oncol; 2016 May; 141(2):341-347. PubMed ID: 26921784
[TBL] [Abstract][Full Text] [Related]
10. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.
Hernández-López R; Lorincz AT; Torres-Ibarra L; Reuter C; Scibior-Bentkowska D; Warman R; Nedjai B; Mendiola-Pastrana I; León-Maldonado L; Rivera-Paredez B; Ramírez-Palacios P; Lazcano-Ponce E; Cuzick J; Salmerón J;
Clin Epigenetics; 2019 Oct; 11(1):140. PubMed ID: 31606044
[TBL] [Abstract][Full Text] [Related]
11. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
Leeman A; Del Pino M; Marimon L; Torné A; Ordi J; Ter Harmsel B; Meijer CJLM; Jenkins D; Van Kemenade FJ; Quint WGV
Int J Cancer; 2019 Jan; 144(1):160-168. PubMed ID: 30098013
[TBL] [Abstract][Full Text] [Related]
12. Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes.
Verhoef VM; van Kemenade FJ; Rozendaal L; Heideman DA; Bosgraaf RP; Hesselink AT; Melchers WJ; Massuger LF; Bekkers RL; Steenbergen RD; Berkhof J; Snijders PJ; Meijer CJ
Gynecol Oncol; 2015 Apr; 137(1):55-9. PubMed ID: 25667975
[TBL] [Abstract][Full Text] [Related]
13. Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.
Leeman A; Ebisch RMF; Kasius A; Bosgraaf RP; Jenkins D; van de Sandt MM; de Strooper LMA; Heideman DAM; Snijders PJF; Massuger LFAG; Bekkers RLM; Meijer CJLM; van Kemenade FJ; Quint WGV; Melchers WJG
Gynecol Oncol; 2018 Nov; 151(2):311-318. PubMed ID: 30219239
[TBL] [Abstract][Full Text] [Related]
14. FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years.
Vink FJ; Meijer CJLM; Hesselink AT; Floore AN; Lissenberg-Witte BI; Bonde JH; Pedersen H; Cuschieri K; Bhatia R; Poljak M; Oštrbenk Valenčak A; Hillemanns P; Quint WGV; Del Pino M; Kenter GG; Steenbergen RDM; Heideman DAM; Bleeker MCG
Clin Infect Dis; 2023 Feb; 76(3):e827-e834. PubMed ID: 35686306
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation testing with S5 for triage of high-risk HPV positive women.
Adcock R; Nedjai B; Lorincz AT; Scibior-Bentkowska D; Banwait R; Torrez-Martinez N; Robertson M; Cuzick J; Wheeler CM;
Int J Cancer; 2022 Oct; 151(7):993-1004. PubMed ID: 35477862
[TBL] [Abstract][Full Text] [Related]
16. Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of
Kremer WW; Dick S; Heideman DAM; Steenbergen RDM; Bleeker MCG; Verhoeve HR; van Baal WM; van Trommel N; Kenter GG; Meijer CJLM; Berkhof J
J Clin Oncol; 2022 Sep; 40(26):3037-3046. PubMed ID: 35512257
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study.
Kelly HA; Chikandiwa A; Sawadogo B; Gilham C; Michelow P; Lompo OG; Omar T; Zan S; Magooa P; Segondy M; Nagot N; Meda N; Delany-Moretlwe S; Mayaud P;
PLoS Med; 2021 Mar; 18(3):e1003528. PubMed ID: 33661957
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
19. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis.
Kelly H; Benavente Y; Pavon MA; De Sanjose S; Mayaud P; Lorincz AT
Br J Cancer; 2019 Nov; 121(11):954-965. PubMed ID: 31616037
[TBL] [Abstract][Full Text] [Related]
20. Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease.
Babion I; De Strooper LMA; Luttmer R; Bleeker MCG; Meijer CJLM; Heideman DAM; Wilting SM; Steenbergen RDM
Epigenetics; 2019 Jun; 14(6):558-567. PubMed ID: 30955437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
